Upregulation of insulin receptor signaling is a promising approach to treat obesity and diabetes [28,30], and the action of glucose-lowering agents, such as GLP-1 and extendin-4, is usually accompanied by the increased Irs2 expression [28,30,31]. Here, IRS2 is linked to diabetes mellitus.